Extracorporeal photopheresis (ECP) for chronic graft versus host disease (cGVHD)

This page provides for two new items added to the MBS for extracorporeal photopheresis treatments for chronic graft versus host disease (cGVHD) patients who are steroid dependent, intolerant, or refractory from 1 March 2022.

Page last updated: 31 March 2022

From 1 March 2022, the Australian Government is making changes to Medicare-funded services to support high-value care and ensure patients with chronic graft versus host disease following allogenic haematopoietic stem cell transportation have access to the most appropriate treatment.

PDF version Extracorporeal photopheresis {ECP} for chronic graft versus host disease {cGHVD} (PDF 255 KB)
Word version Extracorporeal photopheresis {ECP} for chronic graft versus host disease {cGHVD} (Word 88 KB)


In this section